Who are HER3-DXd's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BIZENGRI, KN026.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/her3-dxd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

HER3-DXd — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HER3-DXd (HER3-DXd) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER3-targeting antibody-drug conjugate. Area: Oncology.

phase 2 HER3-targeting antibody-drug conjugate HER3 Oncology Biologic Live · refreshed every 30 min

Target snapshot

HER3-DXd (HER3-DXd) — Merck Sharp & Dohme LLC. HER3-DXd is a HER3-targeting antibody-drug conjugate.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HER3-DXd TARGET	HER3-DXd	Merck Sharp & Dohme LLC	phase 2	HER3-targeting antibody-drug conjugate	HER3
BIZENGRI	ZENOCUTUZUMAB-ZBCO	MERUS N.V.	marketed		HER2, HER3
KN026	KN026	Shanghai JMT-Bio Inc.	phase 3	Bispecific monoclonal antibody	HER2 and HER3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER3-targeting antibody-drug conjugate class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HER3-DXd — Competitive Intelligence Brief. https://druglandscape.com/ci/her3-dxd. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing